Multidrug resistant tuberculosis

BMJ (Online)

Volumn 350, Issue , 2015, Pages

  Millard, James ^a   Ugarte Gil, Cesar ^b,c   Moore, David A J ^d  

^a BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

^b INSTITUTO DE MEDICINA TROPICAL ALEXANDER VON HUMBOLDT   (Peru)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; BEDAQUILINE; CAPREOMYCIN; CLOFAZIMINE; CYCLOSERINE; DELAMANID; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; TUBERCULOSTATIC AGENT; ISONIAZID; RIFAMPICIN;

ANTIBIOTIC SENSITIVITY; BACTERIUM DETECTION; DIARRHEA; GENOTYPE; HEALTH CARE ACCESS; HUMAN; HYPOTHYROIDISM; INFECTION RISK; INJECTION SITE REACTION; LINE PROBE ASSAY; MEDICATION COMPLIANCE; MENTAL DISEASE; MICROBIOLOGY TEST; MOLECULAR BEACON ASSAY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIA GROWTH INDICATOR TUBE; NEPHROTOXICITY; OTOTOXICITY; PALLIATIVE THERAPY; PATIENT RISK; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PUBLIC HEALTH SERVICE; REVIEW; SEIZURE; TOXIC HEPATITIS; TREATMENT OUTCOME; TUBERCULOSIS CONTROL; DRUG ADMINISTRATION; DRUG COMBINATION; FORECASTING; HEALTH; MICROBIAL SENSITIVITY TEST; MORTALITY; PUBLIC HEALTH; RISK FACTOR; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FORECASTING; GENOTYPE; GLOBAL HEALTH; HUMANS; ISONIAZID; MICROBIAL SENSITIVITY TESTS; PALLIATIVE CARE; PHENOTYPE; PROGNOSIS; PUBLIC HEALTH; RIFAMPIN; RISK FACTORS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84929359261     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.h882     Document Type: Review

References (30)

1. World Health Organization. Global tuberculosis report 2014. WHO, 2014.
2. Sullivan T, Ben Amor Y. What's in a name? The future of drug-resistant tuberculosis classification. Lancet Infect Dis 2013;13:373-6.
3. Anderson LF, Tamne S, Brown T., Watson J, Mullarkey C, Zenner D., et al Transmission of multidrug-resistant tuberculosis in the UK: a cross-sectional molecular and epidemiological study of clustering and contact tracing. Lancet Infect Dis 2014;14:406-15.
4. Furin J, Bayona J, Becerra M., Farmer P, Golubkov A, Hurtado R., et al Programmatic management of multidrug-resistant tuberculosis: models from three countries. Int J Tuberc Lung Dis 2011;15:1294-300.
5. Health Protection Agency. Tuberculosis in the UK 2013 report. HPA, 2013.
6. Keshavjee S, Farmer PE Tuberculosis, drug resistance, and the history of modern medicine. N Engl J Med 2012;367:931-6.
7. Nardell E, Dharmadhikari A. Turning off the spigot: reducing drug-resistant tuberculosis transmission in resource-limited settings. Int J Tuberc Lung Dis 2010;14:1233-43.
8. Caminero JA. Multidrug-resistant tuberculosis: epidemiology, risk factors and case finding. Int J Tuberc Lung Dis 2010;14:382-90.
9. Faustini A, Hall AJ, Perucci CA Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax 2006;61:158-63.
10. Peter JG, Theron G, Pooran A., Thomas J, Pascoe M, Dheda K. Comparison of two methods for acquisition of sputum samples for diagnosis of suspected tuberculosis in smear-negative or sputum-scarce people: a randomised controlled trial. Lancet Resp Med 2013;1:471-8.
11. Martin A, Panaiotov S, Portaels F., Hoffner S, Palomino JC, Angeby K. The nitrate reductase assay for the rapid detection of isoniazid and rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother 2008;62:56-64.
12. Moore DA, Evans CA, Gilman R.H., Caviedes L., Coronel J, Vivar A. Microscopic-observation drug-susceptibility assay for the diagnosis of TB. N Engl J Med 2006;355:1539-50.
13. World Health Organization. Noncommercial culture and drug-susceptibility testing methods for screening patients at risk for multidrug-resistant tuberculosis: policy statement. WHO, 2011.
14. World Health Organization. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children. Policy update. WHO, 2013.
15. Somoskovi A, Deggim V, Ciardo D., Bloemberg GV Diagnostic implications of inconsistent results obtained with the Xpert MTB/Rif assay in detection of Mycobacterium tuberculosis isolates with an rpoB mutation associated with low-level rifampin resistance. J Clin Microbiol 2013;51:3127-9.
16. Zetola NM, Shin SS, Tumedi K.A., Moeti K., Ncube R, Nicol M, et al Mixed Mycobacterium tuberculosis complex infections and false-negative results for rifampin resistance by GeneXpert MTB/RIF are associated with poor clinical outcomes. J Clin Microbiol 2014;52:2422-9.
17. Choi HW, Miele K, Dowdy D., Shah M. Cost-effectiveness of Xpert(R) MTB/RIF for diagnosing pulmonary tuberculosis in the United States. Int J Tuberc Lung Dis 2013;17(10):1328-35.
18. FIND. Price for Xpert® MTB/RIF and FIND country list. Secondary price for Xpert® MTB/RIF and FIND country list 2013. www.finddiagnostics.org/about/what-we-do/successes/find-negotiated-prices/xpert-mtb-rif.html.
19. World Health Organization. Tuberculosis diagnostics fact sheet. Secondary tuberculosis diagnostics fact sheet. www.who.int/tb/publications/tbDiagnostics-factsheet.pdf?ua=1.
20. Hillemann D, Rusch-Gerdes S, Richter E. Evaluation of the Geno Type MTBDR plus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 2007;45:2635-40.
21. Raizada N, Sachdeva KS, Chauhan D.S., Malhotra B., Reddy K, Dave PV, et al Amulti-site validation in India of the line probe assay for the rapid diagnosis of multi-drug resistant tuberculosis directly from sputum specimens. PLoS One 2014;9:e88626.
22. Barnard M, Gey van Pittius NC, van Helden PD, Bosman M, Coetzee G, Warren RM. The diagnostic performance of the GenoType MTBDRplus version 2 line probe assay is equivalent to that of the Xpert MTB/RIF assay. J Clin Microbiol 2012;50:3712-6.
23. Koser CU, Bryant JM, Becq J, Török ME, Ellington MJ, Marti-Renom MA, et al. Whole-genome sequencing for rapid susceptibility testing of M. tuberculosis. N Engl J Med 2013;369:290-2.
24. Chiang CY, Van Deun A, Enarson DA A poor drug-resistant tuberculosis programme is worse than no programme: time for a change. Int J Tuberc Lung Dis 2013;17:714-8.
25. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis 2011. http://whqlibdoc.who.int/publications/2011/9789241501583-eng.pdf.
26. Ahuja SD, Ashkin D, Avendano M., Banerjee R, Bauer M, Bayona J.N., et al Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med 2012;9:e1001300.
27. Van Deun A., Maug AK, Salim M.A., Das PK, Sarker MR, Daru P, et al Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Resp Crit Care Med 2010;182:684-92.
28. Dheda K, Migliori GB The global rise of extensively drug-resistant tuberculosis: is the time to bring back sanatoria now overdue? Lancet 2012;379:773-5.
29. Hughes J, Cox H, Ford N. Sanatoria for drug-resistant tuberculosis: an outdated response. Lancet 2012;379:2148.
30. Stop TB Partnership. The global plan to stop TB 2011-2015: transforming the fight towards elimination of tuberculosis. WHO, 2010.